Staff Profile

I am a biostatistician and genetic epidemiologist with a broad experience in international health research and teaching in both academic and industry settings. Since 1993, I have designed and implemented health studies, analysed clinical trials and conducted training courses in statistical analysis and research methods for government institutions, pharmaceutical companies and international organizations.  Prior to joining Newcastle University in 2022, I have held research and academic appointments at Imperial College London, University of Oxford, University of Göttingen (Germany) and University of the Philippines.

Education and Qualifications
(PhD, MSc, BSc, GradStat, FRSPH, FHEA, PG Cert LTHE)

Ph.D. in Applied Statistics and Empirical Methods (Genetic Epidemiology), Centre for Statistics, Georg-August-Universität Göttingen, Germany
Dr. rer. nat., Faculties of Mathematics and Natural Sciences, Georg-August-Universität Göttingen, Germany
Certificate in Pharmacogenomics in Oncology, Universitätsmedizin Göttingen, Germany
PG Certificate in Learning and Teaching in Higher Education, University of London, United Kingdom
Certificate in Effective Online Tutoring, Department for Continuing Education, University of Oxford, United Kingdom
M.Sc. in Public Health (Biostatistics), University of the Philippines Manila
B.Sc. in Public Health, University of the Philippines Manila

For more information, see: https://jlk.academicians.eu/

My current research interest includes the following:
•    Modelling techniques that could be efficiently applied to answer questions on identification of disease states, treatment efficacy, treatment cost-effectiveness and disease prevention
•    Applications of AI in biomarker studies, healthcare and clinical trials
•    Population and family-based analysis methods in genetics

For a comprehensive list of my research projects and publications, please see: 

https://www.researchgate.net/profile/Jingky_Lozano-Kuehne and ORCID: https://orcid.org/0000-0002-7372-0725

I teach in the following postgraduate modules:

Health Statistics  (HSC8036)
Research Skills and Principles for the Biosciences  (MMB8100 / MMB8101)

• Aravind P, Popat S, Barwick TD, Soneji N, Lythgoe M, Lozano-Kuehne J, Sreter KB, Bergqvist M, Patel NH, Aboagye EO, Kenny LM. [18F]Fluorothymidine(FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed. In: ASCO Annual Meeting. 2022, Chicago, IL, USA: American Society of Clinical Oncology.
• Coombes RC, Badman P, Lozano-Kuehne JP, Macpherson IRJ, Zubairi I, Baird RD, Garcia-Corbacho J, Cresti N, Plummer R, Armstrong AC, Allerton R, Landers D, McLellan L, Lim A, Mouliere F, Seckl M. Results of the Phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nature Communications 2022, 13, 3246.
• Kenny LM, Gilbert FJ, Gopalakrishnan G, Aravind P, Barwick T, Patel N, Hiscock DR, Boros I, Kealey S, Aigbirhio FI, Lozano-Kuehne J, Cleator SJ, Fleming B, Riddle P, Ahmad R, Chua S, Johnston SRD, Mansi J, Cook GJ, Aboagye EO. The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [¹⁸F]GE-226, a first-in-patient study. In: ASCO Annual Meeting. 2022, Chicago, IL, USA: American Society of Clinical Oncology.
• Braga A, Paiva G, Ghorani E, Freitas F, Velarde LGC, Kaur B, Unsworth N, Lozano-Kuehne J, Esteves APVS, Filho JR, Junior JA, Aguiar X, Sarwar N, Elias KM, Horowitz NS, Berkowitz RS, Seckl MJ. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: an international, multicentre, retrospective study. Lancet Oncology 2021, 22(8), 1188-1198.
• Pinato DJ, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Fessas P, Nimkar N, Bettinger D, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang Y-H, Lozano-Kuehne J, Rimassa L, Ang C, Marron TU. Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. Journal for Immunotherapy of Cancer 2020, 8(2), e000726.